NUTM2B and sarcoma: In this study, they included CIC::DUX4 [9,54], BCOR-altered [55], EWSR1::ATF1/CREB1 [56], and YWHAE::NUTM2B sarcomas [57], as well as fusion-negative SRCSs, reflecting the expanding molecular landscape within this spectrum [58].